誘導性多功能幹細胞生產市場規模、佔有率及成長分析（依流程、工作流程、產品、應用、最終用途及地區）－2025-2032 年產業預測

誘導性多功能幹細胞生產市場規模預計在 2023 年達到 15.3 億美元，2024 年達到 16.8 億美元，到 2032 年達到 34.9 億美元，預測期內（2025-2032 年）的複合年成長率為 9.6%。

幹細胞（iPSC）製造市場在再生醫學和細胞治療領域正在經歷顯著的成長和創新。 iPSC 源自成體細胞並被重新編程為多功能狀態，為個人化治療和疾病建模提供了巨大潛力。這一快速成長的市場是由人們對 iPSC 在藥物發現和各種疾病狀況中的應用的理解不斷加深所推動的。研發和生技公司正在積極開發可擴展、經濟高效的 iPSC 生產技術。雖然學術界、工業界和醫療機構之間的合作正在推動進步，但嚴格的法律規範和道德考量正在塑造格局並凸顯標準化方法的必要性。隨著全球醫療保健的發展，iPS細胞製造市場將繼續擴大，為科學突破和治療解決方案鋪路。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管格局

誘導性多功能幹細胞生產市場規模（按流程和複合年成長率） (2025-2032)

• 市場概覽
• 手動的
• 自動化

誘導性多功能幹細胞生產市場規模（依工作流程和複合年成長率） (2025-2032)

• 市場概覽
• 重新程式設計
• 細胞培養

誘導性多功能幹細胞生產市場規模（按產品和複合年成長率） (2025-2032)

• 市場概覽
• 耗材和套件
• 裝置
• 服務

誘導性多功能幹細胞生產市場規模（依應用）及複合年成長率（2025-2032）

• 市場概覽
• 藥物開發與發現
• 再生醫學
• 毒理學研究
• 疾病模型
• 其他

誘導性多功能幹細胞生產市場規模（依最終用途和複合年成長率） (2025-2032)

• 市場概覽
• 學術研究所
• 生物技術和製藥公司
• 醫院和診所

誘導性多功能幹細胞生產市場規模（依地區分類）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• FUJIFILM Cellular Dynamics（USA）
• Astellas Pharma（Japan）
• Thermo Fisher Scientific（USA）
• Takara Bio（Japan）
• Lonza Group（Switzerland）
• Merck KGaA（Germany）
• ReproCELL（Japan）
• STEMCELL Technologies（Canada）
• Fate Therapeutics（USA）
• Cynata Therapeutics（Australia）
• Axol Bioscience（UK）
• Ncardia（Belgium）
• Pluricell Biotech（Brazil）
• Evotec（Germany）
• BioTime（USA）
• Cellular Engineering Technologies（USA）
• StemoniX（USA）
• BrainXell（USA）
• EMD Millipore（USA）
• R&D Systems（USA）

結論和建議

Induced Pluripotent Stem Cells Production Market size was valued at USD 1.53 billion in 2023 and is poised to grow from USD 1.68 billion in 2024 to USD 3.49 billion by 2032, growing at a CAGR of 9.6% during the forecast period (2025-2032).

The triggered pluripotent stem cell (iPSC) manufacturing market is experiencing remarkable growth and innovation within regenerative medicine and cellular therapy. Derived from adult cells and reprogrammed into a pluripotent state, iPSCs offer significant potential for personalized treatments and disease modeling. This burgeoning market is fueled by an increasing understanding of iPSCs' applications in drug discovery and various medical conditions. Researchers and biotech firms are actively developing efficient techniques for scalable and cost-effective iPSC production. Collaborations among academia, industry, and healthcare institutions are driving advancements, while stringent regulatory frameworks and ethical considerations shape the landscape, highlighting the need for standardized practices. As global healthcare evolves, the iPSC manufacturing market is set for continued expansion, paving the way for scientific breakthroughs and therapeutic solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Induced Pluripotent Stem Cells Production market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Induced Pluripotent Stem Cells Production Market Segments Analysis

Global Induced Pluripotent Stem Cells Production Market is segmented by Process, Workflow, Product, Application, End-Use and region. Based on Process, the market is segmented into Manual and Automated. Based on Workflow, the market is segmented into Reprogramming and Cell Culture. Based on Product, the market is segmented into Consumables & Kits, Instruments and Services. Based on Application, the market is segmented into Drug Development & Discovery, Regenerative Medicine, Toxicology Studies, Disease Modeling and Others. Based on End-Use, the market is segmented into Academic & Research Institutes, Biotechnology & Pharmaceutical Companies and Hospitals & Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Induced Pluripotent Stem Cells Production Market

A significant driving force behind the global induced pluripotent stem cells (iPSC) production market is the ongoing advancements in regenerative medicine. These stem cells present substantial potential for creating personalized and effective treatments for various medical conditions, thereby attracting significant investment in research and development. Such innovations not only broaden the applications of iPSCs but also present novel therapeutic options, which significantly propel market growth. The increasing interest from pharmaceutical companies and healthcare institutions further enhances this trend, underscoring the pivotal role that advancements in regenerative medicine play in fostering market expansion and stimulating continued investment in iPSC technologies.

Restraints in the Induced Pluripotent Stem Cells Production Market

One significant constraint facing the global induced pluripotent stem cells (iPSC) production market is the array of ethical and regulatory hurdles. Issues regarding the use of human-derived materials, coupled with concerns about the potential misuse of iPSC technology, have led to the implementation of strict regulations in various regions. These obstacles can impede research initiatives, raise compliance costs, and generate market uncertainty. Consequently, such factors can hinder the pace of iPSC adoption and commercialization, ultimately affecting the growth and development of this promising sector in regenerative medicine and biotechnology.

Market Trends of the Induced Pluripotent Stem Cells Production Market

The global Induced Pluripotent Stem Cells (iPSC) production market is witnessing a significant trend driven by the emergence of iPSC-based disease modeling. Researchers and pharmaceutical companies are increasingly leveraging iPSC technology to develop disease-specific cell lines, facilitating more accurate and personalized modeling of a variety of diseases, including genetic disorders, neurodegenerative conditions, and cardiovascular diseases. This shift not only enhances drug discovery and development processes but also fosters the emergence of targeted and effective therapeutic strategies, ultimately shaping the future landscape of precision medicine. As a result, the demand for iPSC products is expected to surge, propelling market growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape

Global Induced Pluripotent Stem Cells Production Market Size by Process & CAGR (2025-2032)

• Market Overview
• Manual
• Automated

Global Induced Pluripotent Stem Cells Production Market Size by Workflow & CAGR (2025-2032)

• Market Overview
• Reprogramming
• Cell Culture

Global Induced Pluripotent Stem Cells Production Market Size by Product & CAGR (2025-2032)

• Market Overview
• Consumables & Kits
• Instruments
• Services

Global Induced Pluripotent Stem Cells Production Market Size by Application & CAGR (2025-2032)

• Market Overview
• Drug Development & Discovery
• Regenerative Medicine
• Toxicology Studies
• Disease Modeling
• Others

Global Induced Pluripotent Stem Cells Production Market Size by End-Use & CAGR (2025-2032)

• Market Overview
• Academic & Research Institutes
• Biotechnology & Pharmaceutical Companies
• Hospitals & Clinics

Global Induced Pluripotent Stem Cells Production Market Size & CAGR (2025-2032)

• North America (Process, Workflow, Product, Application, End-Use)
  • US
  • Canada
• Europe (Process, Workflow, Product, Application, End-Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Process, Workflow, Product, Application, End-Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Process, Workflow, Product, Application, End-Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Process, Workflow, Product, Application, End-Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• FUJIFILM Cellular Dynamics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ReproCELL (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• STEMCELL Technologies (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fate Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cynata Therapeutics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axol Bioscience (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ncardia (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pluricell Biotech (Brazil)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioTime (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellular Engineering Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• StemoniX (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BrainXell (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EMD Millipore (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• R&D Systems (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations